Cardiomyopathy Trial, Recruiting NCT06409585 Sponsor: University of Edinburgh Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT06409585
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

General requirements (apply to all groups):

  • People aged between 30 and 90 years old, male or female
  • People who are willing and able to give their signed agreement to participate before any study procedures begin

Heart failure with preserved pumping function (HFpEF) group:

  • People who have been diagnosed with a type of heart failure where the heart still pumps normally but has trouble relaxing, causing symptoms such as breathlessness, tiredness, and swelling, confirmed by an ultrasound of the heart

Hypertrophic cardiomyopathy group:

  • People who have a confirmed diagnosis of hypertrophic cardiomyopathy, where the heart muscle walls are thicker than normal (confirmed by imaging), without another medical reason to explain the thickening — or with slightly less thickening but supported by genetic factors, family history, or other test results

High blood pressure with heart changes group:

  • People who have had a diagnosis of high blood pressure for at least one year, with evidence on heart ultrasound that the heart walls have become thicker as a result

Arrhythmogenic cardiomyopathy group:

  • People who have a confirmed diagnosis of a specific type of heart muscle disease affecting the right side of the heart, based on internationally recognised diagnostic criteria from 2010

Myocarditis group:

  • People diagnosed with inflammation of the heart muscle within the past month, confirmed by a combination of chest pain, heart scan results, blood test results showing heart injury markers, and either clear coronary arteries or specific findings on a cardiac MRI

Takotsubo cardiomyopathy group:

  • People diagnosed within the past month with a temporary heart condition sometimes called "broken heart syndrome," based on European Society of Cardiology guidelines from 2018

Cardiac sarcoidosis group:

  • People who have had a confirmed diagnosis of sarcoidosis affecting the heart for at least one year, supported by tissue sample results and one or more specific heart-related findings such as unexplained heart rhythm problems, reduced heart pumping function, or abnormal results on specialised heart scans, and where other causes have been reasonably ruled out

Who may not be able to join:

  • People who are unable or unwilling to give their informed consent to participate
  • People who have claustrophobia or who are unable to lie flat for the required imaging scans (PET/MR or PET/CT)
  • People whose kidneys are not functioning well enough, based on a specific blood test result (eGFR below 30 mL/min/1.73m²) (confirm with trial site)
  • Women who are currently pregnant or breastfeeding
  • People who have a known allergy to iodine or gadolinium contrast agents used in medical imaging
  • People for whom CT scanning is not medically appropriate for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Edinburgh
Registry
ClinicalTrials.gov
Start date
1 May 2023
Est. completion
1 August 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Standardised uptake values; Target-to-background ratio

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov